Tandem Diabetes Care Inc. (NASDAQ:TNDM) closed the previous session at $59.21, up by 2.01 or 3.51% higher on its price over the last trading period. Shares of the company have traded -7.47% down in the last 5 days, with the price reaching as high as $63.90 since 11/01/19. The stock however has recovered +4.44% since hitting 5-day low of $56.61. The TNDM stock is -10.25% lower than the $65.88 top value it marked over a period of month. Tandem Diabetes Care Inc. (NASDAQ:TNDM) has a 52-week price range of $26.40- $74.81. The stock is 50.65% up year-to-date. Can TNDM go on to record further gains or will the drop below $57.20 be witnessed again in coming days?
In comparison, let’s see recent movement of other stocks the recent users of Yahoo Finance’s stock information-accessing system have also looked at before they searched Tandem Diabetes Care Inc. (TNDM). Shares of DexCom Inc. (NASDAQ:DXCM) changed $41.58 or a gain of 27.16% to close at $194.70, while the stock of Johnson & Johnson (NYSE:JNJ) gained nearly 0.36% in the last session to close at price of $131.43. Insulet Corporation (NASDAQ:PODD) advanced $4.88 in value, or 3.05% to see deals exchanging hands at $164.87 in the last period. Medtronic plc (NYSE:MDT) dropped -$0.07 or about -0.07 to see its shares trade at $106.80.
The total number of analysts who have rated TNDM as a buy is 9, with just 0 of 12 recommending it as a Sell. 12 analysts of the 0 rated it as underweight; while 2 advised Hold and a further 1 say the stock is Overweight.
Lets us now look at some key statistics for the company and see what they tell us about its books. Tandem Diabetes Care Inc. has a market valuation of $3.31 billion, with its Enterprise Value at $3.24 billion. The enterprise value (EV) is -2.16% off Tandem Diabetes Care Inc.’s market cap. Shares traded in the last session stood at 1645709 while the average trading volume is 1.29 million. Insiders own 5.14% of the shares institutions own 86.70% as outstanding shares currently stand at 57.93 million. When we look at the 20-day simple moving average, TNDM is -3.44%, while that moves to -4.52% over its 50-day SMA and the SMA200 is -4.25%.
When we look at the consensus estimate for TNDM shares, we find that Wall Street analysts have given the average target price of $77.83. The earnings estimate for the current quarter is -0.05, higher than the -0.13 expected for the next quarter. The stock has earnings per share estimate ranging between a low of -0.21 and a high of 0.10, with the coefficient variance at -198.98. For this fiscal year, the estimate climbs to 12.00 versus the 12.00 expected for the next year. TNDM has current-year EPS range between a low of -0.68 and a high of -0.37, with the coefficient variance at -18.58.
The company’s trailing 12-month price-to-sales ratio is 11.76. In terms of profitability, the company has a profit margin of -19.50% and a trailing 12-month (ttm) operating margin of -11.80%. The company’s gross margin is 52.00%. TNDM is one of the hottest stocks right now and that shows in its potential upside on returns with a -25.70% ROA for the last 12 months and a return on equity (ROE) of -42.90% over the same period.
For the fiscal quarter ending 12/30/2018, Tandem Diabetes Care Inc. had revenue of $109.48M. The earnings per share for the most recent quarter were 0.02. The EPS for the recent quarter beat consensus estimates by $0.22 per share after analysts had predicted -$0.2. EPS posted in 3 out of the last 4 quarters have beaten analysts’ estimates.
The investor community is excited about the TNDM stock, with the Barchart 88% Sell showing that the stock could be headed for a massive downtrend. The stock’s 1-month chart already shows that the stock is 7.66% up and -9.92% lower in the last 3 months. Its 12-month performance is showing the stock trending higher by 51.00%. There might be a slight pullback as $58.49 is the first resistance point and if crossed $59.78 should come in play as the second resistance level. TNDM could see support around 56.26 and will later test the 55.32 support.